Omu Anzala is a Professor in the Department of Medical Microbiology at the University of Nairobi, Kenya, and Director of KAVI – Institute of Clinical Research (KAVI - ICR). He obtained his medical training at the University of Nairobi in Kenya; a Diploma in Epidemiology at Tufts University in USA; a PhD in Virology and Immunology at the University of Manitoba, Canada and Postdoctoral Fellow at Molecular Immunology Institute, Institute of Molecular Medicine (IMM), Oxford University, UK. Anzala is the leading HIV vaccine investigator in Kenya and was one of the founders of KAVI in 2001 as the HIV Vaccine Research Unit in Kenya, and part of moving it to its current status as an Institute of Clinical Research in 2013. KAVI-ICR is now a fully-fledged Institute of the University of Nairobi under his leadership. He was co-PI of the first HIV vaccine trial in Kenya, the second in Africa, using a DNA plasmid. He has subsequently been PI or co-PI for 11 IAVI-funded HIV vaccine trials in adults and the first pediatric HIV vaccine trial in Kenya. Anzala has a diverse background in HIV prevention research well-suited to the area of integrated prevention trials. His research has focused on the immunological and genetic correlates of long-term survival and immunologic non-progression among HIV-infected sex workers in Kenya. Related experience includes a RCT of azithromycin prophylaxis for STI and HIV, an intermittent PrEP RCT as well as multiple epidemiology studies in at-risk populations including acute HIV infection, mucosal immunology and broadly neutralising antibody identification in HIV-infected subjects. He was a consultant for Merck HIV Vaccine Network between 2010 to 2013 and also served on the European & Developing Countries Clinical Trials Partnership (EDCTP) Clinical Committee between 2011 to 2013. He has authored over 91 peer-reviewed publications, and supervised and mentored over 23 Masters and 6 PhD students to successful completion of their studies, and will continue to do the same for many more.